SCIENTIFIC WORK

1. Microbiological characteristic of the experimental use of “Autobiotic” on the model of antibiotic – induced dysbiosis in old rats / T. Ivakhniuk, O. Makarenko, Yu. Ivakhniuk, O. Molozhava // Modern Science –Moderní věda : Prague, Czech Republic. – 2018. – № 6. – Р. 107-113.

2. In vitro test-research of the indigenous intestinal microflora of the patients with Alzheimer disease / T. Ivakhniuk, Yu. Ivakhniuk, O. Makarenko, O. Molozhva, R. Dovgan // Modern Science –Moderní věda : Prague, Czech Republic. – 2019. – № 4. – Р. 136-142.

3. The role of PIK3CA mutations in the development of breast cancer (a literature review) / A.O. Pryvalova, I.O. Vynnychenko, V.Yu. Harbuzova, O.I. Vynnychenko, Yu.V. Moskalenko // Zaporozhye medical journal. – 2020. – V. 22, №4(121). – С. 554-560. https://doi.org/10.14739/2310-1210.2020.4.208402

4. Kuzenko O, Kuzenko Ye., Demin Yu. Enterosgel role in neurodegenerative changes in the retina rats under the influence of Cr (VI) – induced retinopathy by study morphological changes in dynamic. ScienceRise:Medical Science. 2021; 1(40): 14-20

5. Kuzenko OV, Kuzenko EV, Dyomin Yu.A. Investigation of the protective properties of methyl silicic acid hydrogel in relation to neurotoxicity induced by Cr (VI) in the optic nerve of rats. Ophthalmological journal. 2021; 1: 62-69.

6. Targeted therapy for non-small cell lung cancer focus on EGFR oncogenic mutation (literature review)/O. M. Smorodska, Yu. V. Moskalenko, I. O. Vynnychenko, O. I.[et al.] // Medicni perspektivi.- 2021 – Т. 26, № 2.- p. 8-11.

Scopus Author ID: https://www.scopus.com/authid/detail.uri?authorId=24781268000

h-index: 16

ORCID ID: https://orcid.org/0000-0002-2339-6509

1. The role of PIK3CA mutations in the development of breast cancer (a literature review) / A.O. Pryvalova, I.O. Vynnychenko, V.Yu. Harbuzova, O.I. Vynnychenko, Yu.V. Moskalenko // Zaporozhye medical journal. – 2020. – V. 22, №4(121). – С. 554-560. https://doi.org/10.14739/2310-1210.2020.4.208402
2. Targeted therapy for non-small cell lung cancer focus on EGFR oncogenic mutation (literature review)/O. M. Smorodska, Yu. V. Moskalenko, I. O. Vynnychenko, O. I.[et al.] // Medicni perspektivi.- 2021 – Т. 26, № 2.- p. 8-11.
3. Moskalenko Y, Kurochkin A, Vynnychenko I, Kravets O, Piddubnyi A, Moskalenko R, Potapov O. Toluidine blue for the detection of sentinel lymph nodes in patients with thyroid cancer. Contemp Oncol (Pozn). 2022;26(4):259-267. doi: 10.5114/wo.2022.124585. Epub 2022 Dec 30. PMID: 36816393; PMCID: PMC9933357.
4. Shah, M. A., Udrea, A. A., Bondarenko, I., Mansoor, W., Sánchez, R. G., Sarosiek, T., … & Ajani, J. A. (2022). Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies. Cancers, 14(5), 1168.
5. Bedke, J., Rini, B. I., Plimack, E. R., Stus, V., Gafanov, R., Waddell, T., … & Powles, T. (2022). Health-related quality of life analysis from KEYNOTE-426: pembrolizumab plus axitinib versus sunitinib for advanced renal cell carcinoma. European Urology, 82(4), 427-439.
6. de Castro Jr, G., Rizvi, N. A., Schmid, P., Syrigos, K., Martin, C., Yamamoto, N., … & NEPTUNE Investigators. (2023). NEPTUNE: phase 3 study of first-line Durvalumab plus tremelimumab in patients with metastatic NSCLC. Journal of Thoracic Oncology, 18(1), 106-119.
7. Psyrri, A., Fayette, J., Harrington, K., Gillison, M., Ahn, M. J., Takahashi, S., … & KESTREL Investigators. (2023). Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study. Annals of Oncology, 34(3), 262-274.
8. Ren, S., Feng, J., Ma, S., Chen, H., Ma, Z., Huang, C., … & Zhou, C. (2023). KEYNOTE‐033: randomized phase 3 study of pembrolizumab vs docetaxel in previously treated, PD‐L1‐positive, advanced NSCLC. International Journal of Cancer, 153(3), 623-634.
9. Plimack, E. R., Powles, T., Stus, V., Gafanov, R., Nosov, D., Waddell, T., … & Rini, B. I. (2023). Pembrolizumab Plus Axitinib Versus Sunitinib as First-Line Treatment of Advanced Renal Cell Carcinoma: 43-Month Follow-up of the Phase 3 KEYNOTE-426 Study. European Urology, 84(5), 449-454.
10. Plimack, E. R., Powles, T., Stus, V., Gafanov, R., Nosov, D., Waddell, T., … & Rini, B. I. (2023). Corrigendum to” Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study”[Eur. (2023)]. European urology, 84(5), e123-e124.

11. Corrigendum to “Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study” [Eur. Urol. (2023)] Primack, Elizabeth R. et al. European Urology, Volume 84, Issue 5, e123 – e124

Scopus Author ID: https://www.scopus.com/authid/detail.uri?authorId= 57193309806

h-index: 1

ORCID ID: https://orcid.org/0000-0002-5398-0298

Research ID: ABG-1458-2020

Google Scholar: https://scholar.google.com.ua/citations?hl=uk&user=8tetJHcAAAAJ

h-index: 2

Research Gate: https://www.researchgate.net/profile/Yuliia-Moskalenko-2

1. The role of PIK3CA mutations in the development of breast cancer (a literature review) / A.O. Pryvalova, I.O. Vynnychenko, V.Yu. Harbuzova, O.I. Vynnychenko, Yu.V. Moskalenko // Zaporozhye medical journal. – 2020. – V. 22, №4(121). – С. 554-560. https://doi.org/10.14739/2310-1210.2020.4.208402
2. Targeted therapy for non-small cell lung cancer focus on EGFR oncogenic mutation (literature review)/O. M. Smorodska, Yu. V. Moskalenko, I. O. Vynnychenko, O. I.[et al.] // Medicni perspektivi.- 2021 – Т. 26, № 2.- p. 8-11.
3. Smorodska O, Moskalenko Y, Vynnychenko I, Vynnychenko O, Kostuchenko V. Modern vector in treatment of patients with lung cancer: tyrosine kinase inhibitors in epidermal growth factor receptor mutations (literature review). Med. perspekt. [Internet]. 2021Jun.18 [cited 2021Sep.20];26(2):4-11. Available from: http://journals.uran.ua/index.php/2307-0404/article/view/234379
4. Piddubnyi, A., Kolomiiets, O., Danilchenko, S., Stepanenko, A., Moskalenko, Y., & Moskalenko, R. (2023). The Prospects of Using Structural Phase Analysis of Microcalcifications in Breast Cancer Diagnostics. Diagnostics, 13(4), 737.

5. Moskalenko, Y. (2024). Biological mechanisms of resistance to immune checkpoint inhibitors and overcoming this resistance: Challenges in medical oncology. Regulatory Mechanisms in Biosystems, 15(1), 83-91. https://doi.org/10.15421/022412

Scopus Author ID: https://www.scopus.com/authid/detail.uri?authorId=57219858916

h-index: 2

ORCID ID: https://orcid.org/0000-0003-4021-2334

1.  Liubchak, V. V., Khomenko, L. M., Kovalishyn, M. P., Ilina, V. V., Babar, T. V., & Sikora, V. V. (2021). New marketing tools in the blood service to optimize quality management.
   

Scopus Author ID: 57720919100

h-index: 0

ORCID ID: https://orcid.org/0000-0002-9577-0272

Google Scholar:https://scholar.google.com/citations?view_op=list_works&hl=uk&user=ouTGJgcAAAAJ

Research Gate:https://www.researchgate.net/profile/Kovchun-Viktor

1. Kachkovska V, Kovchun A, Kovchun V., Prystupa L.The role of Low-Dose CT scan in the early diagnosis of malignant neoplasms of different localization. European Respiratory Journal 2023, 62: PA5348.